
Johnson & Johnson, a global leader in healthcare, has announced the launch of its new corporate and visual identity in Egypt, bringing together its pharmaceutical and medical technology segments under the unified Johnson & Johnson brand.
This strategic transformation reflects the company’s strong commitment to delivering innovative and personalized healthcare solutions, grounded in the latest advancements in science and technology, to address some of the most pressing health challenges in Egypt and globally.
As part of this transition, Janssen—its pharmaceutical arm—will become Johnson & Johnson Innovative Medicine (J&J Innovative Medicine), while Johnson & Johnson MedTech (J&J MedTech) will continue operating in the medical technology space under the same name.

Aligned with this milestone, Johnson & Johnson is participating in the Africa Health ExCon, where it is introducing its new identity, reaffirming its commitment to fostering dialogue around the future of healthcare in the region.
During the event, the company is also hosting a panel discussion bringing together leading healthcare experts and specialists to explore how innovation is reshaping the future of treatment and improving patient outcomes—further supporting collaboration and knowledge exchange to advance healthcare in Egypt and across Africa.
Commenting on this transformation, Ahmed El Hofy, Managing Director of Johnson & Johnson Innovative Medicine in Egypt, Jordan, and Northeast Africa, said: “This transformation represents a pivotal strategic milestone in our journey and reinforces our commitment to delivering innovative and personalized healthcare solutions for patients in Egypt.. We believe that health goes beyond treatment—it is a holistic human experience. That is why every step we take is guided by a deep understanding of patients’ needs and daily challenges”.
He added:“While our name is evolving, our purpose and commitment remain unchanged. We continue to build on our strong legacy of scientific innovation and the trust we have earned from our partners in Egypt’s healthcare ecosystem.. Through this transformation, we aim to further strengthen our ability to deliver advanced therapies across critical areas such as oncology, immunology, hematology, and mental health—ultimately making a meaningful difference in patients’ lives.”
He continued: “At Johnson & Johnson, innovation goes beyond developing medicines. It also includes how care is delivered, how we engage with patients, and how we build impactful partnerships with healthcare stakeholders.. We look forward to continuing our collaboration with partners across Egypt to help shape a healthier future for all”.



